BRPI0516583A - composição farmacêutica e método de tratamento de uma infecção bacteriana - Google Patents

composição farmacêutica e método de tratamento de uma infecção bacteriana

Info

Publication number
BRPI0516583A
BRPI0516583A BRPI0516583-0A BRPI0516583A BRPI0516583A BR PI0516583 A BRPI0516583 A BR PI0516583A BR PI0516583 A BRPI0516583 A BR PI0516583A BR PI0516583 A BRPI0516583 A BR PI0516583A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
bacterial infection
treating
tazobactam
piperacillin
Prior art date
Application number
BRPI0516583-0A
Other languages
English (en)
Inventor
Jonathan Marc Cohen
Mahdi Fawzi
Syed M Shah
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0516583A publication Critical patent/BRPI0516583A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçãO FARMACêUTICA E MéTODO DE TRATAMENTO DE UMA INFECçãO BACTERIANA. A invenção proporciona uma composição farmacêutica compreendendo piperacilina, tazobactam, um ácido aminocarboxílico, e um tampão num diluente de lactato de sódio. A invenção se refere ainda, a um método de tratamento de uma infecção bacteriana e uma condição LR num indivíduo, compreendendo a administração ao indivíduo, de uma quantidade eficaz de uma composição farmacêutica compreendendo piperacilina, tazobactam, um ácido aminocarboxílico e um tampão num diluente de lactato de sódio.
BRPI0516583-0A 2004-10-14 2005-10-12 composição farmacêutica e método de tratamento de uma infecção bacteriana BRPI0516583A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61887204P 2004-10-14 2004-10-14
US71917705P 2005-09-22 2005-09-22
PCT/US2005/036938 WO2006044600A1 (en) 2004-10-14 2005-10-12 Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent

Publications (1)

Publication Number Publication Date
BRPI0516583A true BRPI0516583A (pt) 2008-09-16

Family

ID=35520532

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516583-0A BRPI0516583A (pt) 2004-10-14 2005-10-12 composição farmacêutica e método de tratamento de uma infecção bacteriana

Country Status (14)

Country Link
US (1) US20060084639A1 (pt)
EP (1) EP1799209A1 (pt)
JP (1) JP2008516967A (pt)
KR (1) KR20070110256A (pt)
AU (1) AU2005295644A1 (pt)
BR (1) BRPI0516583A (pt)
CA (1) CA2581303A1 (pt)
CR (1) CR9056A (pt)
EC (1) ECSP077387A (pt)
IL (1) IL182354A0 (pt)
MX (1) MX2007004490A (pt)
NO (1) NO20071711L (pt)
RU (1) RU2007111484A (pt)
WO (1) WO2006044600A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
ITMI20070568A1 (it) * 2007-03-22 2008-09-23 Acs Dobfar Spa Comosizione farmaceutica sterile iniettabile avente piperacillina sodica e tazobactam sodico come principi attivi
US20090075966A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tazobactam
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
EA030662B1 (ru) 2010-11-25 2018-09-28 Аллекра Терапойтикс Гмбх β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ
WO2013036783A2 (en) 2011-09-09 2013-03-14 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
WO2013042140A2 (en) * 2011-09-23 2013-03-28 Manu Chaudhary Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2022106630A1 (en) * 2020-11-20 2022-05-27 Xellia Pharmaceuticals Aps Stable formulations comprising piperacillin and/or tazobactam
WO2022106611A1 (en) * 2020-11-20 2022-05-27 Xellia Pharmaceuticals Aps Novel compositions of beta-lactam compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
US20020132220A1 (en) * 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
EP1499341A4 (en) * 2002-04-18 2010-10-27 Univ Iowa Res Found METHOD FOR INHIBITING AND TREATING BACTERIAL BIOFILMS WITH METAL CHELATE IMAGES
EP1578930A4 (en) * 2002-06-27 2008-07-02 Centocor Inc CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
PL1468697T3 (pl) * 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań

Also Published As

Publication number Publication date
WO2006044600A1 (en) 2006-04-27
AU2005295644A1 (en) 2006-04-27
NO20071711L (no) 2007-07-12
CA2581303A1 (en) 2006-04-27
EP1799209A1 (en) 2007-06-27
CR9056A (es) 2007-09-07
US20060084639A1 (en) 2006-04-20
MX2007004490A (es) 2007-05-08
RU2007111484A (ru) 2008-11-20
KR20070110256A (ko) 2007-11-16
IL182354A0 (en) 2007-09-20
JP2008516967A (ja) 2008-05-22
ECSP077387A (es) 2007-05-30

Similar Documents

Publication Publication Date Title
ECSP077387A (es) Composiciones que contienen piperacilina, tazobactam y un ácido aminocarboxílico en un diluyente de lactato de sodio
Charalampakis et al. A follow‐up study of peri‐implantitis cases after treatment
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
NZ593823A (en) Compositions and methods for the treatment or the prevention of infections by e. coli
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2010045656A3 (en) Novel sglt2 inhibitor dosage forms
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
RU2014127120A (ru) Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
EA201270116A1 (ru) Применение лекарственной формы для наружного нанесения, содержащей хитозан
Flanagan Implant placement in failed endodontic sites: a review
ATE528311T1 (de) Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
ZA202407225B (en) Salt and crystal form of dipeptidyl peptidase inhibitor compound
AR029544A1 (es) Composiciones y metodos para tratar infecciones bacterianas
EP2047850A3 (en) Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
SE0401631D0 (sv) New Composition
UA89204C2 (ru) Композиция, которая содержит пиперациллин, тазобактам и аминокарбоновую кислоту в лактате натрия как разбавителе
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
RU2008129232A (ru) Способ лечения туберкулеза легких у больных вич-инфекцией
BR0311463A (pt) Composições compreendendo uma bactéria do gênero dietzia que são úteis para o tratamento de paratuberculose em ruminantes e método para a cultura da bactéria

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.